Nasal cavity inverting papilloma
disease diseaseOn this page
Also known as inverting papilloma of nasal cavityinverting papilloma of the nasal cavitynasal cavity inverted papillomanasal cavity Schneiderian papilloma, inverted type
Summary
Nasal cavity inverting papilloma (MONDO:0003065) is a disease. A subtype of nasal cavity neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | nasal cavity inverting papilloma |
| Mondo ID | MONDO:0003065 |
| DOID | DOID:4633 |
| NCIT | C8194 |
| UMLS | C0280336 |
| MedGen | 79106 |
| Is cancer (heuristic) | no |
Also known as: inverting papilloma of nasal cavity · inverting papilloma of the nasal cavity · nasal cavity inverted papilloma · nasal cavity Schneiderian papilloma, inverted type
Disease family
This is a subtype of nasal cavity neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › otorhinolaryngologic disease › nasal disorder › nasal cavity disorder › nasal cavity neoplasm › nasal cavity inverting papilloma
Related subtypes (2): nasal cavity cancer, benign neoplasm of nasal cavity
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.